Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications (Q38758162)

6 September 2017

title

Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications (English)

1 reference

6 September 2017

Maximilian Stahl

1 reference

6 September 2017

Amer M Zeidan

series ordinal

1 reference

6 September 2017

language of work or name

English

0 references

publication date

13 February 2017

1 reference

6 September 2017

1 reference

6 September 2017

volume

123

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

1703-1713

1 reference

Myelodysplastic Syndromes

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Myelodysplastic syndromes: what do hospitalists need to know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Myelodysplastic syndromes: toward a risk-adapted treatment approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Emerging biological therapies for the treatment of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Bone marrow transplantation for myelodysplastic syndrome--who? when? and which?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Recent developments in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Clinical and biological implications of driver mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Signal transduction inhibitors in treatment of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

The role of the immune system in myelodysplasia: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Epigenetics in Cancer: A Hematological Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

The novel mechanism of lenalidomide activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Immune surveillance of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Innate and adaptive immune cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Thalidomide: a novel template for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

How we treat lower-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Thrombopoietin receptor agonists in primary immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

T-cell costimulation--biology, therapeutic potential, and challenges

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

Lenalidomide in MDS: 4th time's a charm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

Long Day's Journey Into Night for Lower-Risk Myelodysplastic Syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

Immunosuppressive therapy for hypoplastic myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30585

7 January 2021

Identifiers

DOI

10.1002/CNCR.30585

1 reference

6 September 2017

1 reference